These substances are related to the DEA’s interest in researching hallucinogenic controlled products for clinical tests and research. The DEA asserts that it wants to support the regulated trials of schedule 1 substances, so increasing the production quota explains why this move is essential. The DEA also wants to research the requirements for manufacturing new drugs and the kind of impact marijuana has on the body. These steps are taken to work towards the Food and Drug Administration’s possibilities to approve a new drug.
New Jersey’s THC beverage market is heading into the most consequential stretch of its short…
Mormon Wives star Mikayla Matthews says medical cannabis was “literally life-changing” for her nerve pain…
Chains reorder every two weeks and earn twice the discounts. Independents stock the same breadth…
We head to Canna Country Farms in Humboldt for Legendary Strains to discover the Ocimene…
Cannabis advocates should take the lesson here too. The industry doesn't need to inflate its…
Twenty patient associations from across northeastern Brazil are meeting in Fortaleza this month, inside a…